Structure-directed discovery of potent non-peptidic inhibitors of human urokinase that access a novel binding subsite

Structure

Volumn 8, Issue 5, 2000, Pages 553-563

  Nienaber, Vicki L ^a   Davidson, Donald ^a   Edalji, Rohinton ^a   Giranda, Vincent L ^a   Klinghofer, Vered ^a   Henkin, Jack ^a   Magdalinos, Peter ^a   Mantei, Robert ^a   Merrick, Sean ^a   Severin, Jean M ^a   Smith, Richard A ^a   Stewart, Kent ^a   Walter, Karl ^a   Wang, Jieyi ^a   Wendt, Michael ^a   Weitzberg, Moshe ^a   Zhao, Xumiao ^a   Rockway, Todd ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Drug design; Inhibitors; Tumor metastasis; Urokinase; X ray crystallography

Indexed keywords

2 NAPHTHAMIDINE; BENZOTHIOPHENE 2 CARBOXAMIDINE; PLASMINOGEN ACTIVATOR INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BASEMENT MEMBRANE; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME SPECIFICITY; METASTASIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

EID: 0034657792     PISSN: 09692126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-2126(00)00136-2     Document Type: Article

References (58)

1. Behrendt N., Ronne E., Ploug M., Petri T., Lober D. The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. J. Biol. Chem. 265:1990;6453-6460.
2. Schmitt M., Janicke F., Moniwa N., Chucholowski N., Pache Z. Tumor-associated urokinase-type plasminogen activator: biological and clinical significance. Biol. Chem. Hoppe Seyler. 373:1992;611-622.
3. Duffy M.J. Plasminogen activators and cancer. Blood Coagul. Fibrinolysis. 1:1990;681-687.
4. Busso N., Pleclat V., So A., Sappino A-P. Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints. Ann. Rheum. Dis. 56:1997;550-557.
5. Ronday H.K., Verheijen J.H.et al. Bone matrix degradation by the Plasminogen activation system. Possible mechanism of bone destruction in arthritis. Br. J. Rheumatol. 36:1997;9-15.
6. Carmeliet P., Collen D.et al. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat. Genet. 17:1997;439-444.
7. Noda-Heiny H., Daugherty A., Sobel B.E. Augmented urokinase receptor expression in atheroma. Arterioscler. Thromb. Vasc. Biol. 15:1995;37-43.
8. Heymans S., Carmeliet P.et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat. Med. 5:1999;1135-1142.
9. Kohn E.C. Invasion and metastasis: biology and clinical potential. Pharmacol. Ther. 52:1991;235-244.
10. Reuning U., Schmitt M.et al. Multifunctional potential of the plasminigen activation system in tumor invasion and metastasis. Int. J. Oncol. 13:1998;896-906.
11. Shapiro R.L., Rifkin D.B.et al. Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals. Cancer Res. 56:1996;3597-3604.
12. Evans D., Sloan-Stakleff K., Arvan M., Guyton D. Time and dose dependency of the suppression of pulmonary metastasis of rat mammary cancer by amiloride. Clin. Exp. Metastasis. 16:1998;353-357.
13. Banerji A., Fernandes A., Bane S., Ahire S. The field bean protease inhibitor has the potential to suppress B16F10 melanoma cell lung metastasis in mice. Cancer Lett. 129:1998;15-20.
14. Rabbani S., Harakidas P., Davidson D., Henkin J., Mazar A. Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator. Int. J. Cancer. 63:1995;840-845.
15. Alonso D.F., Tejera A.M., Farias E.F., Bal de Kier Joffe E., Bomez D.E. Inhibition of mammary tumor cell adhesion, migration, and invasion by the selective synthetic urokinase inhibitor B428. Anticancer Res. 18:1998;4499-4504.
16. Alonso D., Bal de Kier Joffe E.et al. Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model. Breast Cancer Res. Treat. 40:1996;209-223.
17. Tressler R.J., Rosenberg S.et al. Urokinase receptor antagonists: discovery and application to in vivo models of tumor growth. APMIS. 107:1999;168-173.
18. Ignar D.M., Emerson D.L.et al. Inhibition of establishment of primary and micrometastatic tumors by a urokinase plasminogen activator receptor antagonist. Clin. Exp. Metastasis. 16:1998;9-20.
19. Mueller B.M., Yu Y.B., Laug W.E. Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid/scid mice. Proc. Natl Acad. Sci. USA. 92:1995;205-209.
20. Foekens J.A., Kramer M.D.et al. Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res. 55:1995;1423-1427.
21. Fleisher M. Prognostic markers other than hormone receptors in breast cancer. J. Clin. Ligand Assay. 21:1998;41-46.
22. Grondahl-Hansen J., Brunner N.et al. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients. Clin. Cancer Res. 3:1997;233-239.
23. Bajou K., Foidart J.M.et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat. Med. 4:1998;923-928.
24. Kim S.J., Takai S.et al. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1 and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter bases. Clin. Cancer Res. 4:1998;177-182.
25. Harbeck N., Schmitt M.et al. Prognostic impact of tumor biological factors on survival in node-negative breast cancer. Anticancer Res. 18:1998;2187-2197.
26. Ke S.H., Coombs G.S., Tachias K., Corey D.R., Madison E.L. Optimal subsite occupancy and design of a selective inhibitor of urokinase. J. Biol. Chem. 272:1997;20456-20462.
27. Spraggon G., Jones E.Y.et al. The crystal structure of the catalytic domain of human urokinase-type plasminogen activator. Structure. 3:1995;681-691.
28. Tidwell R., Geratz J., Dubovi E. Aromatic amidines: comparison of their ability to block respiratory syncytial virus induced cell fusion and to inhibit plasmin, urokinase, thrombin, and trypsin. J. Med. Chem. 26:1983;294-298.
29. Towle M.J., Littlefield B.A.et al. Inhibition of urokinase by 4-substituted benzo(b)thiophene-2-carboxamidines: an important new class of selective low molecular weight urokinase inhibitor. Cancer Res. 53:1993;2553-2559.
30. Bridges A.J., Lee A., Schwartz C.E., Towle M.J., Littlefield B.A. The synthesis of three 4-substituted benzo[b]thiophene-2-carboxamidines as potent and selective inhibitors of urokinase. Bioorg. Med. Chem. 1:1993;403-410.
31. Sturzebecher J., Markwardt F. Synthetische Inhibitoren der Serinproteinasen. Pharmazie. 33:1978;599-602.
32. Yang H., Henkin J., Kim K.H., Greer J. Selective inhibition of urokinase by substituted phenylguanidines: quantitative structure-activity relationship analyses. J. Med. Chem. 33:1990;2956-2961.
33. Renatus M., Bode W., Huber R., Sturzebecher J., Stubbs M. Structural and functional analyses of benzamidine-based inhibitors in complex with trypsin: implications for the inhibition of factor Xa, t-PA and urokinase. J. Med. Chem. 41:1998;5445-5456.
34. Nienaber V., Wang J., Davidson D., Henkin J. Re-engineering of human urokinase provides a system for structure-based drug design at high resolution and reveals a novel binding subsite. J. Biol. Chem. 275:2000;7239-7248.
35. Das J., Kimball S.D. Thrombin active site inhibitors. Bioor. Med. Chem. 3:1995;999-1007.
36. Sanderson P.E., Naylor-Olsen A.M. Thrombin inhibitor design. Curr. Med. Chem. 5:1998;289-304.
37. Kamata K., Kawamoto H., Honma T., Iwama T., Kim S.H. Structural basis for chemical inhibition of human blood coagulation. Proc. Natl Acad. Sci. USA. 9:1998;6630-6635.
38. Brandstetter H., Engh R.A.et al. X-ray structure of active site-inhibited clotting factor Xa. Implications for drug design and substrate recognition. J. Biol. Chem. 271:1996;29988-29992.
39. Bode W., Schwager P. The refined crystal structure of bovine beta-trypsin at 1.8 Å resolution. II. Crystallographic refinement, calcium binding site, benzamidine binding site and active site at pH 7.0. J. Mol. Biol. 98:1975;693-717.
40. Bode W., Mayr I., Baumann U., Huber R., Stone S.R. The refined 1.9 Å crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J. 8:1989;3467-3475.
41. Padmanabhan K., Huber R.et al. Structure of human des(1-45) factor Xa at at 2.2 Å resolution. J. Mol. Biol. 232:1993;947-966.
42. Renatus M., Stubbs M.et al. Structural mapping of the active site specificity determinants of human tissue-type plasminogen activator. Implications for the design of low molecular weight substrates and inhibitors. J. Biol. Chem. 272:1997;21713-21719.
43. Geratz J.D., Shaver S., Tidwell R.R. Inhibitory effect of amidino-substituted heterocylic compounds on the amidase activity of plasmin and of high and low molecular weight urokinase and on urokinase-induced plasminogen activation. Thromb. Res. 24:1981;73-83.
44. Engh R.A., von der Saal W.et al. Enzyme flexibility, solvent and 'weak' interactions characterize thrombin-ligand interactions: implications for drug design. Structure. 4:1996;1353-1362.
45. Stubbs M., Huber R., Bode W. Crystal structures of factor Xa specific inhibitors in complex with trypsin: structural grounds for inhibition of factor Xa and selectivity against thrombin. FEBS Lett. 375:1995;103-107.
46. von der Saal W., Sauer J.et al. Syntheses and selective inhibitory activities of terphenyl-bisamidines for serine proteases. Arch. Pharm. 329:1996;73-82.
47. Jackson R. Update on computer-aided drug design. Curr. Opin. Biotechnol. 6:1995;646-651.
48. Verlinde C.L., Hol W.G. Structure-based drug design: progress, results and challenges. Structure. 2:1994;577-587.
49. Stubbs M., Bode W. A player of many parts: the spotlight falls on thrombin's structure. Thromb. Res. 69:1993;1-58.
50. Fevig J., Wexler R.et al. Rational design of boropeptide thrombin inhibitors: β,β-dialkyl-phenethylglycine P2 analogs of DuP 714 with greater selectivity over complement factor I and an improved safety profile. Bioorg. Med. Chem. Lett. 8:1998;301-306.
51. Collen D., Lijnen H. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy. Thromb. Haemost. 74:1995;167-171.
52. Marquart M., Walter J., Deisenhofer J., Bode W., Huber R. The geometry of the reactive site and of the peptide groups in trypsin, trypsinogen and its complexes with inhibitors. Acta Crystallogr. B. 39:1983;480.
53. Emi M., Matsubara K.et al. Cloning, characterization and nucleotide sequences of two cDNAs encoding human pancreatic trypsinogens. Gene. 41:1986;305-310.
54. Otwinowski Z., Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276:1997;307-326.
55. Brünger A.T. X-PLOR version 3.1 manual. 1993;Yale University Press, New Haven, Conneticut.
56. Engh R.A., Huber R. Accurate bond and angle parameters for X-ray protein-structure refinement. Acta Crystallogr. A. 47:1991;392-400.
57. Wagner G., Walsmann P.et al. Synthetic inhibitors of serum proteinases. Part 15: Antitrypsin, antiplasmin, and antithrombin effect of 2-amidino-6-alkoxy- and aralkoxynaphthalenes. Pharmazie. 32:1977;761-763.
58. Nicholls A., Sharp K., Honig B. Protein folding and association: insights from interfacial and thermodynamic properties of hydrocarbons. Proteins. 11:1991;281-296.